global trials on for hepatitis--B indication : British multinational Glaxo has registered its potential blockbuster anti-AIDS drug, lamivudine (also known as 3-TC), with the Drugs Controller General of India (DCGI). Glaxo's move is significant, given that lamivudine is presently undergoing clinical trials in several countries for the treatment of hepatitis--B, an affliction estimated to have 42.5 million Indian carriers.